Sugi Predict

Sugi Predict / Compounds / SCHEMBL20670908

SCHEMBL20670908

SCHEMBL20670908

CC(C)C(=O)[C@H](C)NC(=O)C(NC(=O)CCCCCN1C(=O)C=CC1=O)C(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 7/20 0.46
▸ PTGS2 P35354 7/20 0.46
▸ MGLL Q99685 5/20 0.41
▸ FAAH O00519 3/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ MAPT P10636 3/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ NPSR1 Q6W5P4 3/20 0.41
▸ LMNA P02545 2/20 0.41
▸ PKM P14618 2/20 0.41
▸ HTT P42858 2/20 0.41
▸ HSP90AA1 P07900 1/20 0.41
▸ TLR9 Q9NR96 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ XBP1 P17861 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ GPR35 Q9HC97 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18937810 1.00 PTGS1 (0.46) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL22267879 1.00 PTGS1 (0.46) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL26149732 1.00 PTGS1 (0.46) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL2561561 0.91 PTGS1 (0.49) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL2560233 0.91 PTGS1 (0.49) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL16069853 0.91 PTGS1 (0.46) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL2560238 0.91 PTGS1 (0.49) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL12285559 0.91 PTGS1 (0.49) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL18774100 0.91 PTGS1 (0.49) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL19257592 0.91 PTGS1 (0.46) PTGS1PTGS2MGLLFAAHALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11191771-B2 Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors SEAGEN INC. (US) 2021-12-07 — — US disclosed
US-20190262354-A1 COMBINATIONS OF PBD-BASED ANTIBODY DRUG CONJUGATES WITH FLT3 INHIBITORS SEATTLE GENETICS, INC. (US) 2019-08-29 — — US disclosed
US-20190023801-A1 BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS SEATTLE GENETICS, INC. (US) 2019-01-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190262354-A1 COMBINATIONS OF PBD-BASED ANTIBODY DRUG CONJUGATES WITH FLT3 INHIBITORS FLT3, PBDC1, ABL1 PTGS1 4772/4885PTGS2 4771/4885MGLL 4259/4885
US-11191771-B2 Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors FLT3, PBDC1, ABL1 PTGS1 4772/4885PTGS2 4771/4885MGLL 4259/4885
US-20190023801-A1 BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS CD47, IGSF11, BCR PTGS1 4167/4885PTGS2 4409/4885MGLL 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.